The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations
- PMID: 38741145
- PMCID: PMC11089770
- DOI: 10.1186/s13053-024-00277-5
The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations
Abstract
Background: It has not been clearly established if skin cancer or melanoma are manifestations of BRCA1 or BRCA2 mutation carrier status. Estimating the risk of skin cancer is an important step towards developing screening recommendations.
Methods: We report the findings of a prospective cohort study of 6,207 women from North America who carry BRCA1 or BRCA2 mutations. Women were followed from the date of baseline questionnaire to the diagnosis of skin cancer, to age 80 years, death from any cause, or the date of last follow-up.
Results: During the mean follow-up period of eight years, 3.7% of women with a BRCA1 mutation (133 of 3,623) and 3.8% of women with a BRCA2 mutation (99 of 2,584) reported a diagnosis of skin cancer (including both keratinocyte carcinomas and melanoma). The cumulative risk of all types of skin cancer from age 20 to 80 years was 14.1% for BRCA1 carriers and 10.7% for BRCA2 carriers. The cumulative risk of melanoma was 2.5% for BRCA1 carriers and 2.3% for BRCA2 carriers, compared to 1.5% for women in the general population in the United States. The strongest risk factor for skin cancer was a prior diagnosis of skin cancer.
Conclusion: The risk of non-melanoma skin cancer in women who carry a mutation in BRCA1 or BRCA2 is similar to that of non-carrier women. The risk of melanoma appears to be slightly elevated. We suggest that a referral to a dermatologist or primary care provider for BRCA mutation carriers for annual skin examination and counselling regarding limiting UV exposure, the use of sunscreen and recognizing the early signs of melanoma might be warranted, but further studies are necessary.
Keywords: BRCA1; BRCA2; Basal cell carcinoma; Melanoma; Skin cancer.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.Ann Ital Chir. 2019;90:1-2. Ann Ital Chir. 2019. PMID: 30872561
-
BRCA1 and BRCA2 families and the risk of skin cancer.Fam Cancer. 2010 Dec;9(4):489-93. doi: 10.1007/s10689-010-9377-y. Fam Cancer. 2010. PMID: 20809262
-
BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.Mol Genet Genomic Med. 2019 Mar;7(3):e493. doi: 10.1002/mgg3.493. Epub 2019 Jan 16. Mol Genet Genomic Med. 2019. PMID: 30652428 Free PMC article.
-
The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.Prostate. 2019 Jun;79(8):880-895. doi: 10.1002/pros.23795. Epub 2019 Mar 22. Prostate. 2019. PMID: 30900310
-
Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.J Clin Oncol. 2004 Feb 15;22(4):735-42. doi: 10.1200/JCO.2004.05.055. J Clin Oncol. 2004. PMID: 14966099 Review.
Cited by
-
Skin Signals: Exploring the Intersection of Cancer Predisposition Syndromes and Dermatological Manifestations.Int J Mol Sci. 2025 Jun 26;26(13):6140. doi: 10.3390/ijms26136140. Int J Mol Sci. 2025. PMID: 40649916 Free PMC article. Review.
References
-
- Global Cancer Observatory. Cancer Today. Lyon, France: International Agency for Research on Cancer. https://gco.iarc.fr, accessed [01/13/2022]. 2020.
LinkOut - more resources
Full Text Sources
Miscellaneous